0001179110-14-008431.txt : 20140514
0001179110-14-008431.hdr.sgml : 20140514
20140514182737
ACCESSION NUMBER: 0001179110-14-008431
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140514
FILED AS OF DATE: 20140514
DATE AS OF CHANGE: 20140514
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Theravance Biopharma, Inc.
CENTRAL INDEX KEY: 0001583107
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET
CITY: GEORGE TOWN, GRAND CAYMAN
STATE: E9
ZIP: KY1-1104
BUSINESS PHONE: 650-808-6000
MAIL ADDRESS:
STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET
CITY: GEORGE TOWN, GRAND CAYMAN
STATE: E9
ZIP: KY1-1104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: THERAVANCE INC
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36033
FILM NUMBER: 14843061
BUSINESS ADDRESS:
STREET 1: 901 GATEWAY BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6508086000
MAIL ADDRESS:
STREET 1: 901 GATEWAY BLVD
CITY: S. SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER NAME:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
3
1
edgar.xml
FORM 3 -
X0206
3
2014-05-14
0
0001583107
Theravance Biopharma, Inc.
TBPH
0001080014
THERAVANCE INC
901 GATEWAY BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
0
1
0
Ordinary Shares
33100000
D
As of the date of this report, Theravance Biopharma, Inc. is a wholly owned subsidiary of Theravance, Inc. (NASDAQ: THRX). Theravance has announced its intention to distribute to its stockholders ordinary shares of Theravance Biopharma via a stock dividend. Any Theravance Biopharma shares held by Theravance that are not needed for the stock dividend of one Theravance Biopharma share for every 3.5 Theravance shares outstanding at the record date will be contributed by Theravance to Theravance Biopharma and will not be outstanding shares immediately following the stock dividend.
Bradford J. Shafer, General Counsel and Secretary
2014-05-14